- $204.76bn
- $227.44bn
- $45.81bn
- 85
- 28
- 50
- 54
REG - AstraZeneca PLC - Forxiga approved in the EU for CKD
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Saphnelo approved in the US for SLE
AnnouncementREG - AstraZeneca PLC - AZN: H1 2021 Results
AnnouncementREG - AstraZeneca PLC - Ultomiris recommended in EU for children with PNH
AnnouncementREG - AstraZeneca PLC - Directorate Change
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Acquisition of Alexion completed
AnnouncementREG - BMO Cap & Inc InvTst - Portfolio Update
AnnouncementREG - AstraZeneca PLC - Imfinzi approved in China for extensive-stage SCLC
AnnouncementREG - AstraZeneca PLC - Status on US FDA Advisory Committee for roxadustat
AnnouncementREG - FTSE Russell AstraZeneca PLC - AstraZeneca
AnnouncementREG - Competition and Mkts - Merger Update: AstraZeneca / Alexion
AnnouncementREG - AstraZeneca PLC - AstraZeneca-Alexion transaction cleared in the UK
AnnouncementREG - AstraZeneca PLC - Tezepelumab granted FDA Priority Review for asthma
AnnouncementREG - AstraZeneca PLC - AstraZeneca-Alexion transaction cleared in the EU
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Forxiga recommended in EU for patients with CKD
Announcement